Literature DB >> 10024309

Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet.

P T Shih1, M L Brennan, D K Vora, M C Territo, D Strahl, M J Elices, A J Lusis, J A Berliner.   

Abstract

Atherosclerotic lesion development is characterized by the recruitment of leukocytes, principally monocytes, to the vessel wall. Considerable interest has been focused on the adhesion molecule(s) involved in leukocyte/endothelial interactions. The goal of the present study was to determine the role of the very late antigen-4 (VLA-4) integrin/ligand interaction in fatty streak development using murine models. Because alpha4 null mice are not viable, a peptidomimetic was used to block VLA-4-mediated leukocyte binding. The ability of a synthetic peptidomimetic of connecting segment-1 (CS-1 peptide) to block the recruitment of leukocytes and the accumulation of lipid in the aortic sinus of either wild-type mice (strain C57BL/6J) or mice with a low-density lipoprotein null mutation (LDLR-/-) maintained on an atherogenic diet was assessed. The active (Ac) CS-1 peptide or scrambled (Sc) CS-1 peptide was delivered subcutaneously into mice using a mini osmotic pump. Mice were exposed to the peptide for 24 to 36 hours before the onset of the atherogenic diet. In C57BL/6J mice, leukocyte entry into the aortic sinus, as assessed by en face preparations, was inhibited by the active peptide (Ac=28+/-4, Sc=54+/-6 monocytes/valve; P=0.004). Additionally, frozen sections stained with Oil Red O were analyzed to assess lipid accumulation in the aortic sinus. C57BL/6J mice that received the (Ac) compound demonstrated significantly reduced lesion areas as compared with mice that received the (Sc) peptide (Ac=4887+/-4438 microm2, Sc=15 009 +/-5619 microm2; P<0.0001). In a separate study, LDLR-/- mice were implanted with pumps containing either the (Ac) or (Sc) peptide before initiation of the atherogenic diet. Because LDLR-/- mice fed a chow diet displayed small lesions at 14 weeks, the effects of the peptide seen in these animals represented a change in early lipid accumulation rather than initiation. By using whole-mount preparations, the (Ac) but not the (Sc) peptide significantly reduced the area of lipid accumulation in the aortic sinus, resulting in an approximate 66% decrease. Plasma analysis from all studies revealed concentrations of peptide to be present at levels previously determined by in vitro analysis to block adhesion. (Ac) CS-1 peptide, which blocks VLA-4 on the leukocyte surface, is effective in reducing leukocyte recruitment and lipid accumulation in the aortic sinus. The present study provides in vivo evidence that the VLA-4 integrin plays an important role in the initiation of the atherosclerotic lesion and lipid accumulation, and it suggests a potential therapeutic strategy for this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024309     DOI: 10.1161/01.res.84.3.345

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  17 in total

1.  VCAM-1 is critical in atherosclerosis.

Authors:  K Ley; Y Huo
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice via the complement system.

Authors:  L Persson; J Borén; A Nicoletti; G K Hansson; M Pekna
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium.

Authors:  Y Huo; C Weber; S B Forlow; M Sperandio; J Thatte; M Mack; S Jung; D R Littman; K Ley
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  The potential role of RTN3 in monocyte recruitment and atherosclerosis.

Authors:  Yaqin Chen; Rong Xiang; Shuiping Zhao
Journal:  Mol Cell Biochem       Date:  2011-10-02       Impact factor: 3.396

Review 5.  Glycosyltransferases, glycosylation and atherosclerosis.

Authors:  Qianghong Pu; Chao Yu
Journal:  Glycoconj J       Date:  2014-10-08       Impact factor: 2.916

Review 6.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

Review 7.  Monocyte-endothelial cell interactions in the development of atherosclerosis.

Authors:  Javier Mestas; Klaus Ley
Journal:  Trends Cardiovasc Med       Date:  2008-08       Impact factor: 6.677

Review 8.  Role of cell adhesion molecules and immune-cell migration in the initiation, onset and development of atherosclerosis.

Authors:  Zhang Chi; Alirio J Melendez
Journal:  Cell Adh Migr       Date:  2007-10-20       Impact factor: 3.405

Review 9.  Experimental models investigating the inflammatory basis of atherosclerosis.

Authors:  Ahmed Soliman; Patrick Kee
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

10.  Interferon-γ: Promising therapeutic target in atherosclerosis.

Authors:  Joe We Moss; Dipak P Ramji
Journal:  World J Exp Med       Date:  2015-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.